Direct control of hepatic glucose production by interleukin-13 in mice
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Hyperglycemia is a result of impaired insulin action on glucose production and disposal, and a major target of antidiabetic therapies. The study of insulin-independent regulatory mechanisms of glucose metabolism may identify new strategies to lower blood sugar levels. Here we demonstrate an unexpected metabolic function for IL-13 in the control of hepatic glucose production. IL-13 is a Th2 cytokine known to mediate macrophage alternative activation. Genetic ablation of Il-13 in mice (Il-13-/-) resulted in hyperglycemia, which progressed to hepatic insulin resistance and systemic metabolic dysfunction. In Il-13-/- mice, upregulation of enzymes involved in hepatic gluconeogenesis was a primary event leading to dysregulated glucose metabolism. IL-13 inhibited transcription of gluconeogenic genes by acting directly on hepatocytes through Stat3, a noncanonical downstream effector. Consequently, the ability of IL-13 to suppress glucose production was abolished in liver cells lacking Stat3 or IL-13 receptor α1 (Il-13rα1), which suggests that the IL-13Rα1/Stat3 axis directs IL-13 signaling toward metabolic responses. These findings extend the implication of a Th1/Th2 paradigm in metabolic homeostasis beyond inflammation to direct control of glucose metabolism and suggest that the IL-13/Stat3 pathway may serve as a therapeutic target for glycemic control in insulin resistance and type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
M-1/M-2 Macrophages and the Th1/Th2 Paradigm
Mills, C. D., Kincaid, K., Alt, J. M., Heilman, M. J., & Hill, A. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.12.6166 · Cited by 3,287 · cited 2×
“BALB/c mice exhibit a much stronger Th2 response (accompanied by a weak Th1 response) and are less prone to develop metabolic diseases than are C57BL/6 mice (31, 32).”
Alternative Activation of Macrophages: An Immunologic Functional Perspective
Martinez, F. O., Helming, L., & Gordon, S. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132532 · Cited by 2,745 · cited 3×
“To measure gluSTAT6 is known as the main effector of Th2 cytokines in immune cells (16, 43).”
Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB
Cai, D., Yuan, M., Frantz, D. F., Melendez, P. A., Hansen, L., Lee, J., & Shoelson, S. E. (2005) · Nature Medicine · doi:10.1038/nm1166 · Cited by 2,245
Macrophage-specific PPARγ controls alternative activation and improves insulin resistance
Odegaard, J. I., Ricardo-Gonzalez, R. R., Goforth, M. H., Morel, C. R., Subramanian, V., Mukundan, L., Eagle, A. R., Vats, D., Brombacher, F., Ferrante, A. W., et al. (2007) · Nature · doi:10.1038/nature05894 · Cited by 2,107
IKK-β links inflammation to obesity-induced insulin resistance
Arkan, M. C., Hevener, A. L., Greten, F. R., Maeda, S., Li, Z.-W., Long, J. M., Wynshaw-Boris, A., Poli, G., Olefsky, J., & Karin, M. (2005) · Nature Medicine · doi:10.1038/nm1185 · Cited by 1,773
Essential role of Stat6 in IL-4 signalling
Takeda, K., Tanaka, T., Shi, W., Matsumoto, M., Minami, M., Kashiwamura, S.-I., Nakanishi, K., Yoshida, N., Kishimoto, T., & Akira, S. (1996) · Nature · doi:10.1038/380627a0 · Cited by 1,557 · cited 1×
“In fact, IL-4/STAT6 signaling is essential for Th2 cell differentiation (44–46).”
The cellular and signaling networks linking the immune system and metabolism in disease
Osborn, O., & Olefsky, J. M. (2012) · Nature Medicine · doi:10.1038/nm.2627 · Cited by 1,551 · cited 1×
“Genetic models in mice have demonstrated that deletion of key inflammatory mediators improves glucose tolerance in obesity-induced insulin resistance (12).”
Normalization of obesity-associated insulin resistance through immunotherapy
Winer, S., Chan, Y., Paltser, G., Truong, D., Tsui, H., Bahrami, J., Dorfman, R., Wang, Y., Zielenski, J., Mastronardi, F., et al. (2009) · Nature Medicine · doi:10.1038/nm.2001 · Cited by 1,370
Macrophage-mediated inflammation in metabolic disease
Chawla, A., Nguyen, K. D., & Goh, Y. P. S. (2011) · Nature reviews. Immunology · doi:10.1038/nri3071 · Cited by 1,314
Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene
Shimoda, K., van Deursent, J., Sangster, M. Y., Sarawar, S. R., Carson, R. T., Tripp, R. A., Chu, C., Quelle, F. W., Nosaka, T., Vignali, D. A. A., et al. (1996) · Nature · doi:10.1038/380630a0 · Cited by 1,278
Cited by
Energy Metabolism in the Liver
Rui, L. (2014) · Comprehensive Physiology · doi:10.1002/cphy.c130024 · Cited by 1,953
Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus
Foretz, M., Guigas, B., & Viollet, B. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0242-2 · Cited by 686
Foundations of Immunometabolism and Implications for Metabolic Health and Disease
Hotamisligil, G. S. (2017) · Immunity · doi:10.1016/j.immuni.2017.08.009 · Cited by 505
Innate Lymphoid Cells in Inflammation and Immunity
McKenzie, A. N. J., Spits, H., & Eberl, G. (2014) · Immunity · doi:10.1016/j.immuni.2014.09.006 · Cited by 368
Self-citationTargeting inflammation in metabolic syndrome
Welty, F. K., Alfaddagh, A., & Elajami, T. K. (2016) · Translational Research · doi:10.1016/j.trsl.2015.06.017 · Cited by 287
“In contrast, ApoC-III is a 79-aminoacid glycoprotein synthesized by the liver and intestines and an inhibitor of LPL.57 This inhibition leads to an increase in levels of TG.58 ApoC-III also increases TG levels by stimulating the synthesis ofVLDLand preventing its breakdown by inhibiting the binding of VLDL remnants to…”
BackgroundInfluentialCytokines and abnormal glucose and lipid metabolism
Shi, J., Fan, J., Su, Q., & Yang, Z. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00703 · Cited by 282
“On the contrary, genetic deletion of IL-13 in mice resulted in hyperglycemia, which progressed to hepatic insulin resistance and systemic metabolic disturbances (107).”
BackgroundJAK/STAT – Emerging Players in Metabolism
Dodington, D. W., Desai, H. R., & Woo, M. (2018) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2017.11.001 · Cited by 275
Hams, E., Locksley, R. M., McKenzie, A. N. J., & Fallon, P. G. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301176 · Cited by 232
“1A) (11), with Il13 mice demonstrating dysregulated glucose metabolism and glucose in-”
BackgroundSelf-citationStrategies targeting the IL-4/IL-13 axes in disease
May, R. D., & Fung, M. (2015) · Cytokine · doi:10.1016/j.cyto.2015.05.018 · Cited by 166
Bcl11b is essential for group 2 innate lymphoid cell development
Walker, J. A., Oliphant, C. J., Englezakis, A., Yu, Y., Clare, S., Rodewald, H.-R., Belz, G., Liu, P., Fallon, P. G., & McKenzie, A. N. J. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20142224 · Cited by 165
Self-citationInterleukin-13 drives metabolic conditioning of muscle to endurance exercise
Knudsen, N. H., Stanya, K. J., Hyde, A. L., Chalom, M. M., Alexander, R. K., Liou, Y.-H., Starost, K. A., Gangl, M. R., Jacobi, D., Liu, S., et al. (2020) · Science · doi:10.1126/science.aat3987 · Cited by 139
“Generation of Il13 animals in the C57Bl/6J background was described in (13).”
BackgroundSelf-citationGieseck, R. L., Ramalingam, T. R., Hart, K. M., Vannella, K. M., Cantu, D. A., Lu, W.-Y., Ferreira-González, S., Forbes, S. J., Vallier, L., & Wynn, T. A. (2016) · Immunity · doi:10.1016/j.immuni.2016.06.009 · Cited by 132
Epigenetic programming, early life nutrition and the risk of metabolic disease
Block, T., & El-Osta, A. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.09.003 · Cited by 130
Hepatic transcriptional responses to fasting and feeding
Bideyan, L., Nagari, R., & Tontonoz, P. (2021) · Genes & Development · doi:10.1101/gad.348340.121 · Cited by 126
Kahn, D., Macias, E., Zarini, S., Garfield, A., Zemski Berry, K., MacLean, P., Gerszten, R. E., Libby, A., Solt, C., Schoen, J., et al. (2022) · Endocrinology · doi:10.1210/endocr/bqac140 · Cited by 97
Dynamic repression by BCL6 controls the genome-wide liver response to fasting and steatosis
Sommars, M. A., Ramachandran, K., Senagolage, M. D., Futtner, C. R., Germain, D. M., Allred, A. L., Omura, Y., Bederman, I. R., & Barish, G. D. (2019) · eLife · doi:10.7554/elife.43922 · Cited by 66
“Over 80% of Bcl6 mice exhibit myocarditis and over 70% have pulmonary vasculitis with elevated levels of IL-4,–5, and 13, cytokines known to directly impact liver metabolism (Ricardo-Gonzalez et al., 2010; Stanya et al., 2013).”
BackgroundLoss of transcriptional repression by BCL6 confers insulin sensitivity in the setting of obesity
Senagolage, M. D., Sommars, M. A., Ramachandran, K., Futtner, C. R., Omura, Y., Allred, A. L., Wang, J., Yang, C., Procissi, D., Evans, R. M., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.074 · Cited by 44
Sinusoidal communication in chronic liver disease
Gibert-Ramos, A., Andrés-Rozas, M., Pastó, R., Alfaro-Retamero, P., Guixé-Muntet, S., & Gracia-Sancho, J. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0734 · Cited by 20
“As examples, IL-6 and IL-13 inhibit the transcription of gluconeogenic genes acting through STAT-3 (29,30) , while TGFβ inhibits the transcription of enzymes involved in cholesterol biosynthesis and accumulation (31).”
Background
Metadata
- Authors
- Stanya, K. J., Jacobi, D., Liu, S., Bhargava, P., Dai, L., Gangl, M. R., Inouye, K., Barlow, J. L., Ji, Y., Mizgerd, J. P., Qi, L., Shi, H., McKenzie, A. N. J., & Lee, C.-H.
- Venue
- Journal of Clinical Investigation
- Published
- 2012-12-21
- Volume
- 123
- Issue
- 1
- Pages
- 261-271
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2108003067
- Cited by
- 140
- References
- 18
- FWCI
- 6.11
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.